Bayer Begins Over $43 Million OTC Manufacturing Facility Expansion in Pennsylvania – Endpoints News

German pharmaceutical giant Bayer intends to make a significant investment in one of its US plants that makes over-the-counter drugs.

Bayer announced it will spend $43.6 million to expand its facility in Myerstown, PA, a small town east of Harrisburg. Bayer plans to increase the site by 70,000 square feet and have space for installing eight packaging lines and an area for installing solar panels on the roof. The project should be completed by 2025 and create around 50 to 75 jobs.

Much of Bayer’s OTC profile comes from the Myerstown facility, including brands such as Claritin, Midol, Alka-Seltzer and numerous other products that will produce a total of 14.1 billion tablets and 3.9 million liquid liters in 2021. The site covers 68 acres with over half a million square feet and employs over 630 people.

Earlier in the year, Bayer said it plans to invest more than $2.26 billion in its pharmaceutical manufacturing facility over the next three years by expanding facilities in the US and Europe. Big Pharma also plans to modernize and streamline processes at the facility.

Bayer will invest more than $2.26 billion in its pharmaceutical manufacturing over the next three years as it intends to expand sites in both Europe and the United States.

Other manufacturers have also made significant investments in Pennsylvania this year.

West Pharmaceutical Services, a manufacturer of vials, prefillable syringes and self-injection products, will invest $65 million to expand its manufacturing facility in the city of Jersey Shore, PA, a few miles from Williamsport, PA. West also plans to increase headcount at its Exton, PA headquarters.

Almac Group, a global drug substance and pharmaceutical contracting and manufacturing company, is also expanding its North American headquarters in the city of Souderton, PA, northwest of Philadelphia, with the same $65 million investment.

And in the western part of the state, ElevateBio and the University of Pittsburgh say they have signed a 30-year deal for ElevateBio to manufacture cell and gene therapies in Pittsburgh. The agreement provides for ElevateBio to locate its BaseCamp and GMP manufacturing facilities in the city, with the site eventually hosting gene editing, induced pluripotent stem cells (iPSC), and cell, vector and protein engineering efforts.